PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11916527-1 2002 The relationship between p53 gene status and the expression of DR5 and Fas was evaluated as a function of sensitivity of 11 acute lymphoblastic leukemia cell lines to adriamycin, etoposide, vincristine, methotrexate and dexamethasone. Etoposide 179-188 TNF receptor superfamily member 10b Homo sapiens 63-66 16923369-8 2006 Expression of DR5 protein was not detected in SKNDZ cells but an increased DR5 protein expression was found after treatment with adriamycin or etoposide. Etoposide 143-152 TNF receptor superfamily member 10b Homo sapiens 14-17 16923369-8 2006 Expression of DR5 protein was not detected in SKNDZ cells but an increased DR5 protein expression was found after treatment with adriamycin or etoposide. Etoposide 143-152 TNF receptor superfamily member 10b Homo sapiens 75-78 16123594-4 2005 NFkappaB activation induces death receptor 5 (DR5) expression following DNA damaging agent etoposide treatment but not following growth factor EGF treatment. Etoposide 91-100 TNF receptor superfamily member 10b Homo sapiens 28-44 16123594-4 2005 NFkappaB activation induces death receptor 5 (DR5) expression following DNA damaging agent etoposide treatment but not following growth factor EGF treatment. Etoposide 91-100 TNF receptor superfamily member 10b Homo sapiens 46-49 15964798-4 2005 Herein, we determined that etoposide-induced DR5 expression requires the first intronic region of the DR5 gene. Etoposide 27-36 TNF receptor superfamily member 10b Homo sapiens 45-48 15964798-4 2005 Herein, we determined that etoposide-induced DR5 expression requires the first intronic region of the DR5 gene. Etoposide 27-36 TNF receptor superfamily member 10b Homo sapiens 102-105 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Etoposide 66-75 TNF receptor superfamily member 10b Homo sapiens 179-182 12838325-7 2003 Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5. Etoposide 102-111 TNF receptor superfamily member 10b Homo sapiens 249-252 11090076-8 2000 These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis. Etoposide 44-53 TNF receptor superfamily member 10b Homo sapiens 90-93 11803469-2 2002 We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Etoposide 56-65 TNF receptor superfamily member 10b Homo sapiens 205-208 11090076-6 2000 Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels. Etoposide 39-48 TNF receptor superfamily member 10b Homo sapiens 82-85 10706092-3 2000 Here we show that the DNA-damaging chemotherapeutic drugs, cis-diamminedichloroplatinum(II) (CDDP) and etoposide, elicited increased expression of DR5 in human glioma cells. Etoposide 103-112 TNF receptor superfamily member 10b Homo sapiens 147-150 10706092-4 2000 Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA. Etoposide 83-92 TNF receptor superfamily member 10b Homo sapiens 180-183 28702823-0 2017 Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Etoposide 0-9 TNF receptor superfamily member 10b Homo sapiens 112-115 10594023-4 2000 The mechanism of the synergistic effect results from the etoposide-mediated increase in the expression of the death receptors 4 (DR4) and 5 (DR5). Etoposide 57-66 TNF receptor superfamily member 10b Homo sapiens 141-144 10594023-5 2000 Inhibition of NF-kappaB activation by expression of kinase-inactive MEK kinase 1(MEKK1) or dominant-negative IkappaB (DeltaIkappaB) blocked the increase in DR4 and DR5 expression following etoposide treatment. Etoposide 189-198 TNF receptor superfamily member 10b Homo sapiens 164-167 28702823-3 2017 In this work, the DR5 mediated anticancer potential of topoisomerase inhibitor etoposide (ET) and doxorubicin (DOX) against TNBC has been evaluated. Etoposide 79-88 TNF receptor superfamily member 10b Homo sapiens 18-21 28702823-3 2017 In this work, the DR5 mediated anticancer potential of topoisomerase inhibitor etoposide (ET) and doxorubicin (DOX) against TNBC has been evaluated. Etoposide 90-92 TNF receptor superfamily member 10b Homo sapiens 18-21 28702823-4 2017 ET and DOX enhanced the DR5 expression in TNBC cells, whereas non-topoisomerase inhibitors pifithrin-alpha (PIF) and dexamethasone (DEX) failed to do so. Etoposide 0-2 TNF receptor superfamily member 10b Homo sapiens 24-27 27993669-6 2017 Suppression of etoposide-induced cell death correlated with a downregulation of p53 expression, which, among other functions, regulates the expression of death receptor 5, one of the activators of caspase-8. Etoposide 15-24 TNF receptor superfamily member 10b Homo sapiens 154-170 24732433-4 2014 Through this route, WFA acted as an effective DR5 activator capable of potentiating the biologic effects of celecoxib, etoposide, and TRAIL. Etoposide 119-128 TNF receptor superfamily member 10b Homo sapiens 46-49 23124518-2 2012 We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC. Etoposide 43-52 TNF receptor superfamily member 10b Homo sapiens 122-125 23124518-2 2012 We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC. Etoposide 43-52 TNF receptor superfamily member 10b Homo sapiens 127-143 23124518-2 2012 We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC. Etoposide 43-52 TNF receptor superfamily member 10b Homo sapiens 147-155 21751122-8 2011 Etoposide and doxorubicin induced DR5 but not DR4 in NB cell lines. Etoposide 0-9 TNF receptor superfamily member 10b Homo sapiens 34-37 23124518-4 2012 Although TRAIL-R2 expression increased in IMR-32 cells in response to etoposide treatment, cell death was not increased by concurrent treatment with TRAIL compared with etoposide alone, because the cells lacked caspase 8 expression. Etoposide 70-79 TNF receptor superfamily member 10b Homo sapiens 9-17 23124518-7 2012 These results indicate that the etoposide-mediated sensitization of neuroblastoma cells to TRAIL is associated with an increase in TRAIL-R2 expression and requires caspase 8 expression. Etoposide 32-41 TNF receptor superfamily member 10b Homo sapiens 131-139